S. Chowdhury

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

N.W. Clarke, Amin Ali, Fiona C. Ingleby et al. · Annals of Oncology · 2019 · 398 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

Matthew R. Sydes, Melissa Spears, Malcolm D. Mason et al. · Annals of Oncology · 2018 · 250 citations · Full text

Medicine, Oncology, Urology +17

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone

Diletta Bianchini, David Lorente, Alejo Rodríguez‐Vida et al. · European Journal of Cancer · 2013 · 209 citations

Medicine, Oncology, Pharmacology +14

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer

Eric J. Small, Fred Saad, S. Chowdhury et al. · Annals of Oncology · 2019 · 152 citations · Full text

Medicine, Oncology, Pharmacology +17

Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer

S. Chowdhury, Anders Bjartell, Neeraj Agarwal et al. · Annals of Oncology · 2023 · 113 citations · Full text

Medicine, Oncology, Pharmacotherapy +17